Myriad Uranium Enters into Option to Acquire 100% of the Red Basin Uranium Project in New Mexico, USA
Myriad Uranium Corp. (CSE: M) (OTCQB: MYRUF) (FSE: C3Q) ("Myriad" or the "Company") is pleased to announce that it has ...
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.
3 Cloud and AI Stocks to Buy Hand Over Fist in February
T he cloud and artificial intelligence (AI) markets, which are linked together in myriad ways, have both flourished over the ...
Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing
Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...
Why good sex on Valentine's Day could help reduce your cancer risk
Health experts say having a good sex life is linked to several health benefits, including reducing the risk of cancer.
CSU pioneers major AI rollout, sparking myriad concerns over jobs, academic freedom, surveillance
The California State University announced an unprecedented AI initiative, integrating artificial intelligence across all 23 ...
Islanders fall short against high-powered Winnipeg
The Jets brushed aside a first-period deficit with a three-goal second period and then withstood the Islanders' 19-shot ...
Why Drake Maye could hit the ground running in Josh McDaniels' offense
Phil Perry explains how Drake Maye can get a head start on learning Josh McDaniels' Patriots offense during the offseason.
decrypt11d
MYRIAD Launches on Abstract as Mainnet Goes Live
The decentralized prediction market is one of the main apps featured on Abstract’s portal for the Abstract Global Wallet.
Myriad Genetics, Inc.: Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...
Pharmabiz1d
Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay
Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...